The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
About this guideline
Overseas effective date: 1 January 2017
Replaces: EMA/CHMP/748108/2013 Guideline on clinical investigation of medicinal products in the treatment of lipid disorder (Adopted by TGA 1 August 2014)
Note: To be read in conjunction with the Paediatric addendum to CHMP guideline on clinical investigation of medicinal products in the treatment of lipid disorders (EMA/CHMP/494506/2012 (EMEA/CHMP/EWP/213057/2010)
Categories: Clinical efficacy and safety | Cardiovascular system | Lipid disorders
TGA annotations: Nil
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency - external site for further information.
For more information see International scientific guidelines adopted in Australia.